Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.87 |
| ▸ | TUBB | P07437 | 4/20 | 0.87 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.87 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.87 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.87 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.87 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.87 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.87 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.87 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.87 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.87 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.87 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.87 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.87 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | TSHR | P16473 | 1/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.83 |
| ▸ | P4HB | P07237 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mertansine SCHEMBL21095214 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL24235209 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL22762724 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL24776847 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL24917414 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL24823366 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL24336892 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL23140493 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL22580840 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL17754556 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041661-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 | BICYCLETX LIMITED (GB) | 2023-02-09 | — | — | US | disclosed |
| US-20230033370-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 | BICYCLETX LIMITED (GB) | 2023-02-02 | — | — | US | disclosed |
| US-20230021419-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 | BICYCLETX LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| US-20220133733-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD38 | BICYCLERD LTD (GB) | 2022-05-05 | — | — | US | disclosed |
| US-20220133732-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CAIX | BICYCLERD LTD (GB) | 2022-05-05 | — | — | US | disclosed |
| WO-2022079445-A1 | BICYCLIC PEPTIDE LIGAND DRUG CONJUGATES | Bicyclerd Limited (GB) | 2022-04-21 | — | — | WO | disclosed |
| US-20220064218-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD38 | BICYCLETX LIMITED (GB) | 2022-03-03 | — | — | US | disclosed |
| US-20220024983-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 | Bicyclerd Limited (GB) | 2022-01-27 | — | — | US | disclosed |
| US-20220024982-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | BICYCLETX LIMITED (GB) | 2022-01-27 | — | — | US | disclosed |
| US-20220008545-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR FAPa | Bicyclerd Limited (GB) | 2022-01-13 | — | — | US | disclosed |
| WO-2020148530-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD38 | Bicyclerd Limited (GB) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020148526-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CAIX | Bicyclerd Limited (GB) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020128526-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR PD-L1 | BICYCLETX LIMITED (GB) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020128527-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR PD-L1 | Bicyclerd Limited (GB) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020120984-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | BICYCLETX LIMITED (GB) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020120978-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 | Bicyclerd Limited (GB) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020120981-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | BICYCLETX LIMITED (GB) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020120979-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR FAPα | Bicyclerd Limited (GB) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020120983-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | Bicyclerd Limited (GB) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020120980-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR PSMA | Bicyclerd Limited (GB) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064218-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD38 | CD38, CD22, CD40LG | TUBB4A 4324/4885TUBB 4234/4885TUBA3C 3716/4885 |
| US-20220024982-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | MMEL1, MMP3, TIMP3 | TUBB4A 2397/4885TUBB 2117/4885TUBA3C 1040/4885 |
| US-20220008545-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR FAPa | FAP, FIBP, FGFR3 | TUBB4A 2762/4885TUBB 3294/4885TUBA3C 3074/4885 |
| US-20230041661-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 | IL17A, IL23R, IL15 | TUBB4A 2707/4885TUBB 1777/4885TUBA3C 1355/4885 |
| US-20220133733-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD38 | CD38, CD22, TIMCC | TUBB4A 4364/4885TUBB 4236/4885TUBA3C 3344/4885 |
| US-20220024983-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 | IL17A, IL23R, IL15 | TUBB4A 2352/4885TUBB 1482/4885TUBA3C 1085/4885 |
| US-20230021419-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 | IL17A, IL23R, IL15 | TUBB4A 2707/4885TUBB 1777/4885TUBA3C 1355/4885 |
| US-20220133732-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CAIX | CA4, CA2, CA13 | TUBB4A 3712/4885TUBB 3940/4885TUBA3C 3270/4885 |
| US-20230033370-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 | IL17A, IL23R, IL15 | TUBB4A 2707/4885TUBB 1777/4885TUBA3C 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.